United Therapeutics reported $607.8M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Amarin USD 164.2M 15.45M Jun/2026
Ardelyx USD 109.57M 20.96M Mar/2026
Baxter International USD 3.59B 102M Jun/2026
Bayer EUR 33.46B 875M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Moderna USD 2.53B 139M Jun/2026
Omeros USD 85.5M 2.28M Jun/2025
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Teva Pharmaceutical Industries USD 15.65B 2.11B Jun/2026
United Therapeutics USD 607.8M 8.7M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026